BISOPROLOL TABLETS

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

şimdi satın al

Indir Ürün özellikleri (SPC)
24-10-2022

Aktif bileşen:

BISOPROLOL FUMARATE

Mevcut itibaren:

SIVEM PHARMACEUTICALS ULC

ATC kodu:

C07AB07

INN (International Adı):

BISOPROLOL

Doz:

10MG

Farmasötik formu:

TABLET

Kompozisyon:

BISOPROLOL FUMARATE 10MG

Uygulama yolu:

ORAL

Paketteki üniteler:

15G/50G

Reçete türü:

Prescription

Terapötik alanı:

BETA-ADRENERGIC BLOCKING AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0122418002; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2020-01-14

Ürün özellikleri

                                _BISOPROLOL TABLETS _
_Page 1 of 40_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
BISOPROLOL TABLETS
Bisoprolol fumarate tablets
5 mg, 10 mg tablets (oral)
Manufacturer’s Standard
β-adrenoceptor blocking agent
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent, Quebec, Canada
H4R 2P7
www.sivem.ca
Submission Control No: 267679
Date of
Revision:
OCT
24, 2022
_BISOPROLOL TABLETS _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
21
OVERDOSAGE
...............................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 22
STORAGE AND STABILITY
.........................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.........................................................................
25
CLINICAL TRIALS
.............................................................
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Ürün özellikleri Ürün özellikleri Fransızca 24-10-2022

Bu ürünle ilgili arama uyarıları

Belge geçmişini görüntüleyin